The Gamaleya National Research Center for Epidemiology and Microbiology in Russia is planning to commence human clinical trials for a new mRNA-based cancer vaccine designed to treat melanoma, one of the most aggressive forms of skin cancer.
According to a post by BRICS Info on X (formerly Twitter), the innovative vaccine employs personalized medicine technology, integrating AI-driven neoantigen mapping to create highly targeted treatments tailored to each patient’s specific tumor profile.
The statement at the Gamaleya Center confirmed that tailored treatment and the vaccine development and production process takes approximately one week for each patient, allowing for rapid and customized therapeutic intervention. The center, which previously developed the Sputnik V COVID-19 vaccine, is now leveraging its mRNA expertise to address oncology.
Crucially, the treatment is expected to be offered free of charge to eligible patients in Russia, with the goal of a nationwide rollout by the end of 2025.
The vaccine represents a major step forward in the global fight against cancer, particularly for melanoma patients, who often face limited treatment options. Russian health authorities view this initiative as a milestone in precision medicine and a testament to the country’s investment in advanced biotechnological solutions.
If successful, the vaccine could mark one of the first publicly available, AI-personalized cancer treatments, and significantly alter the landscape of global cancer therapy.
Credit: @BRICSinfo via x.com.
Leave a Reply